Novo Nordisk Partners With OpenAI to Accelerate Weight Loss Drug Discovery

Pharmaceutical giant Novo Nordisk has partnered with OpenAI to use artificial intelligence in the race to develop next-generation weight loss drugs, marking one of the most significant AI-pharma collaborations to date. The partnership comes as states are simultaneously dropping Medicaid coverage of GLP-1 drugs like Ozempic due to soaring demand and costs. The deal signals AI's accelerating role in drug discovery while highlighting the tension between innovation and affordability in healthcare.